Oruka Therapeutics (NASDAQ:ORKA) Insider Joana Goncalves Sells 7,000 Shares of Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) insider Joana Goncalves sold 7,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $111.84, for a total value of $782,880.00. Following the sale, the insider directly owned 32,718 shares in the company, valued at approximately $3,659,181.12. The trade was a 17.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joana Goncalves also recently made the following trade(s):

• On Monday, June 15th, Joana Goncalves sold 7,947 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.28, for a total transaction of $550,568.16.

Oruka Therapeutics Trading Up 1.5%

Shares of NASDAQ ORKA opened at $112.66 on Tuesday. Oruka Therapeutics, Inc. has a twelve month low of $14.08 and a twelve month high of $113.04. The firm has a 50-day moving average of $88.49 and a two-hundred day moving average of $63.36. The company has a market capitalization of $7.46 billion, a price-to-earnings ratio of -55.50 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, research analysts predict that Oruka Therapeutics, Inc. will post -2.27 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on ORKA shares. Weiss Ratings raised Oruka Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Wall Street Zen lowered Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday. Piper Sandler restated an “overweight” rating and issued a $180.00 target price on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Guggenheim restated a “buy” rating and issued a $200.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $120.00 target price on shares of Oruka Therapeutics in a research report on Monday, August 3rd. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $134.30.

Hedge Funds Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Algert Global LLC raised its holdings in Oruka Therapeutics by 3.5% during the second quarter. Algert Global LLC now owns 5,380 shares of the company’s stock valued at $512,000 after buying an additional 180 shares in the last quarter. Royal Bank of Canada increased its position in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares during the period. Kennedy Capital Management LLC raised its position in shares of Oruka Therapeutics by 0.9% during the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after buying an additional 420 shares during the last quarter. AlphaCentric Advisors LLC lifted its stake in shares of Oruka Therapeutics by 5.8% in the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after buying an additional 626 shares during the period. Finally, Russell Investments Group Ltd. grew its position in Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after buying an additional 788 shares in the last quarter. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development of novel peptide?based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell?permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.